| Market Cap | 229.29M | P/E | 34.33 | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -35.33M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -12.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -25.00% |
| Dividend | N/A | Price/Book | 7.00 | EPS next 5Y | - | 52W High Chg | -81.00% |
| Recommedations | - | Quick Ratio | 0.11 | Shares Outstanding | 31.80M | 52W Low Chg | 48.00% |
| Insider Own | 71.08% | ROA | -1.04% | Shares Float | 4.21M | Beta | - |
| Inst Own | 57.10% | ROE | 2.69% | Shares Shorted/Prior | 108.56K/9.32K | Price | 7.21 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 783,646 | Target Price | - |
| Oper. Margin | - | Earnings Date | - | Volume | 379,514 | Change | 3.74% |
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
| Raymond James | Strong Buy | May 24, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Munshi Amit | Director Director | Jun 05 | Buy | 4.25 | 117,647 | 500,000 | 617,640 | 06/05/23 |